The Report Covers US Diabetes Devices Companies and It is Segmented by Management Devices (insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Insulin Disposable Pens, and Jet Injectors) and Monitoring Devices (self-Monitoring Blood Glucose and Continuous Glucose Monitoring). The Report Offers the Value (in USD) for the Above Segments.

The Diabetes Care Devices Market is Segmented by Management Devices (Insulin Pumps, Insulin Syringes, and More), Monitoring Devices (Self-Monitoring Blood Glucose and Continuous Glucose Monitoring), by Patient Type (Type-1 Diabetes, Type-2 Diabetes and More), by End User (Hospitals & Clinics, Home-Care Settings and More) and Geography. The Market Forecasts are Provided in Terms of Value (USD).

The global diabetes care devices market is expected to reach USD 64.5 billion in 2024. The sales are expected to grow even higher and will be estimated at USD 117.7 billion in 2034 due to the rising diabetes population. The diabetes care devices market is anticipated to record a CAGR of 6.2% between 2024 and 2034.

Attributes	Description
Estimated Global Diabetes Care Devices Market Size (2024E)	USD 64.5 billion
Projected Global Diabetes Care Devices Market Value (2034F)	USD 117.7 billion
Value-based CAGR (2024 to 2034)	6.2%

Semi-annual Industry Update

Particular	Value CAGR
H1	5.7% (2023 to 2033)
H2	5.2% (2023 to 2033)
H1	4.5% (2024 to 2034)
H2	4.2% (2024 to 2034)

Country-wise Insights

Countries	CAGR 2024 to 2034
India	8.8%
China	8.4%
South Korea	8.1%
Australia	6.7%
France	4.3%
United States	3.4%

Category-wise Insights

Segment	Glucose Monitoring Devices (Product Type)
Value Share (2024)	58.3%

Segment	Diabetes Type II (Indication)
Value Share (2024)	19.7%

Discover the booming US diabetes devices market, projected to reach [estimated 2033 market size in billions] by 2033, with a CAGR of 6.27%. This in-depth analysis covers market trends, key players (Abbott, Medtronic, Dexcom), and growth drivers like continuous glucose monitoring (CGM) and insulin pump advancements. Learn about market segmentation and regional insights. Recent developments include: August 2023: The US Food and Drug Administration (FDA) has granted clearance for Roche's Accu-Chek Solo micropump system, a tubing-free "patch" pump for people with diabetes who use insulin., March 2022: Dexcom released G7 first in the U.K. and was expected to expand the launch across Europe throughout 2022. Meanwhile, the CGM system currently is under review by the Food and Drug Administration for an eventual U.S. release.. Key drivers for this market are: Increasing Number of Preterm and Low-weight Births, Advanced Technology in Fetal and Prenatal Monitoring. Potential restraints include: Stringent Regulatory Procedures. Notable trends are: Growing Diabetes and Obesity Population in the United States.

The Germany Diabetes Devices Market is Segmented by Device (Monitoring Devices [Self-Monitoring Blood Glucose and Continuous Glucose Monitoring] and Management Devices [Insulin Pumps, Insulin Disposable Pens, Insulin Syringes, Cartridges in Reusable Pens, and Jet Injectors]), End User (Homecare and Hospital and Clinics). The Market Provides the Value (in USD) for the Above Segments.

The global diabetes devices market is experiencing robust growth, driven by the increasing prevalence of diabetes worldwide and the rising adoption of advanced technologies for diabetes management. The market, estimated at $XX billion in 2025, is projected to expand at a CAGR of XX% from 2025 to 2033, reaching a value of approximately $YY billion by 2033 (Note: XX and YY represent estimated values based on reasonable industry projections given the provided CAGR and typical market growth for medical devices; exact figures require full dataset). Key drivers include the growing geriatric population, increased awareness about diabetes management, technological advancements leading to more accurate and convenient monitoring devices (like continuous glucose monitors), and the rising preference for insulin pumps over traditional injection methods. Furthermore, the shift towards personalized medicine and the development of connected devices integrating data analysis and remote monitoring capabilities are significantly propelling market expansion. However, high costs associated with advanced diabetes devices, particularly continuous glucose monitors and insulin pumps, pose a significant restraint to market growth, particularly in developing economies. Variations in healthcare reimbursement policies across different regions also present challenges. The market is segmented by device type (e.g., insulin delivery systems, blood glucose monitoring systems, continuous glucose monitoring systems), by end-user (hospitals, clinics, homecare settings), and by region (North America, Europe, Asia-Pacific, etc.). Major players like Medtronic, Sanofi, Bayer, Becton Dickinson, Novo Nordisk, Abbott Laboratories, Roche, Lifescan, B. Braun, Dexcom, and Ypsomed Holdings are actively engaged in research and development, strategic partnerships, and acquisitions to expand their market share and offer innovative solutions. The competitive landscape is characterized by technological advancements, product differentiation, and an increasing focus on improving patient outcomes through integrated care solutions.

The global diabetes care devices market size was USD 33.55 billion in 2024 & is projected to grow from USD 36.40 billion in 2025 to USD 69.91 billion by 2033.
Report Scope:

Report Metric	Details
Market Size in 2024	USD 33.55 Billion
Market Size in 2025	USD 36.40 Billion
Market Size in 2033	USD 69.91 Billion
CAGR	8.50% (2025-2033)
Base Year for Estimation	2024
Historical Data	2021-2023
Forecast Period	2025-2033
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered	By Monitoring Device,By Management Device,By Region.
Geographies Covered	North America, Europe, APAC, Middle East and Africa, LATAM,
Countries Covered	U.S., Canada, U.K., Germany, France, Spain, Italy, Russia, Nordic, Benelux, China, Korea, Japan, India, Australia, Taiwan, South East Asia, UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria, Brazil, Mexico, Argentina, Chile, Colombia,

Diabetes Care Devices Market Outlook

According to our latest research, the global diabetes care devices market size reached USD 29.4 billion in 2024, driven by a surge in diabetes prevalence and technological advancements in care solutions. The market is growing at a robust CAGR of 7.2% and is expected to reach USD 54.7 billion by 2033. This significant growth trajectory is fueled by increasing awareness about diabetes management, rising adoption of advanced monitoring and insulin delivery devices, and supportive government initiatives worldwide. The diabetes care devices market continues to evolve rapidly, offering innovative solutions that enhance patient outcomes and improve quality of life for millions globally.

The primary growth driver for the diabetes care devices market is the escalating prevalence of diabetes worldwide. According to the International Diabetes Federation, more than 537 million adults are living with diabetes as of 2024, and this number is projected to rise steadily in the coming years. The growing burden of both Type 1 and Type 2 diabetes is prompting healthcare providers and patients to seek more effective and convenient solutions for disease management. This trend has led to a surge in demand for blood glucose monitoring devices, insulin delivery systems, and continuous glucose monitoring devices, which are critical for maintaining optimal glycemic control and reducing the risk of diabetes-related complications. Furthermore, the increasing incidence of obesity, sedentary lifestyles, and unhealthy dietary habits are further exacerbating the diabetes epidemic, thereby driving the need for advanced diabetes care devices.

Technological innovation is another crucial factor propelling the diabetes care devices market forward. The integration of digital health technologies, such as mobile applications, cloud-based data management, and wearable sensors, has revolutionized diabetes care by enabling real-time monitoring, personalized feedback, and remote patient management. Continuous glucose monitors (CGMs) and smart insulin pens, for instance, offer patients and healthcare providers valuable insights into glucose trends and insulin usage patterns, facilitating more precise and proactive diabetes management. The development of minimally invasive and non-invasive devices, along with the advent of artificial intelligence and machine learning algorithms, is further enhancing the accuracy, convenience, and user experience of diabetes care solutions. These technological advancements are not only improving clinical outcomes but also increasing patient adherence and satisfaction, thereby contributing to the sustained growth of the diabetes care devices market.

Supportive government policies and reimbursement frameworks are also playing a pivotal role in the expansion of the diabetes care devices market. Many countries are implementing national diabetes prevention and management programs, investing in public health campaigns, and increasing funding for research and innovation in diabetes care. In addition, favorable reimbursement policies for advanced diabetes devices, particularly in developed markets such as North America and Europe, are making these products more accessible to a broader patient population. Collaborations between governments, healthcare organizations, and industry stakeholders are fostering the development and adoption of cost-effective and user-friendly diabetes care solutions. As healthcare systems worldwide prioritize chronic disease management and preventive care, the demand for reliable and efficient diabetes care devices is expected to remain strong in the foreseeable future.

From a regional perspective, North America currently dominates the diabetes care devices market, accounting for the largest share of global revenues. This leadership position is attributed to the high prevalence of diabetes, well-established healthcare infrastructure, and widespread adoption of advanced medical technologies in the region. Europe follows closely, with a strong focus on diabetes research, innovation, and patient education. Meanwhile, the Asia Pacific region is emerging as a lucrative market, driven by rapid urbanization, rising disposable incomes, and increasing awareness about diabetes management. Countries such as China and India are witnessing a surge in diabetes cases, prompting significant investments in healthcare infrastructure and diabetes care solutions. Latin America and the Middle East & Africa are also experiencing steady growth, albei

Diabetes Devices Market was valued at USD 32.63 Billion in 2024 and is projected to reach USD 48.03 Billion by 2032, growing at a CAGR of 5.46% from 2026 to 2032.Global Diabetes Devices Market DriversThe global Diabetes Devices Market is experiencing robust growth, fueled by a confluence of critical factors. As the incidence of diabetes continues to climb worldwide, the demand for innovative and effective tools to manage the condition becomes increasingly vital. This article delves into the primary drivers shaping the expansion of the Diabetes Devices Market, highlighting how each factor contributes to its current trajectory and future potential.Rising Prevalence of Diabetes Worldwide: The escalating global burden of diabetes stands as the paramount driver for the Diabetes Devices Market. According to the International Diabetes Federation (IDF), over half a billion people worldwide are currently living with diabetes, a number projected to increase significantly in the coming decades. This epidemic, driven by factors such as sedentary lifestyles, unhealthy dietary habits, urbanization, and an aging population, creates a vast and ever growing patient pool requiring consistent monitoring and management. The sheer volume of new diagnoses annually translates directly into a higher demand for blood glucose meters, test strips, insulin pens, and continuous glucose monitoring (CGM) systems, making the rising prevalence a foundational catalyst for market expansion.Increasing Adoption of Continuous Glucose Monitoring (CGM) and Insulin Pumps: A significant shift in diabetes management strategies is the accelerating adoption of advanced technologies like Continuous Glucose Monitoring (CGM) systems and insulin pumps. Patients and healthcare providers are increasingly recognizing the superior benefits offered by these devices compared to traditional methods.

Planned monitoring requirements combined with insulin requirements for diabetic pets among dogs and cats create a market need for specialized care devices. Pixel GPS medicine forecasts the market to achieve USD 2,594 million in 2025 but predicts an increase to USD 4,645.5 million by 2035 at a compound annual growth rate (CAGR) of 6%.

Metric	Value
Industry Size (2025E)	USD 2,594 million
Industry Value (2035F)	USD 4,645.5 million
CAGR (2025 to 2035)	6%

Country-Wise Outlook

Country	CAGR (2025 to 2035)
USA	6.4%

Country	CAGR (2025 to 2035)
UK	5.8%

Region	CAGR (2025 to 2035)
European Union	6.0%

Country	CAGR (2025 to 2035)
Japan	5.6%

Country	CAGR (2025 to 2035)
South Korea	6.2%

Segmentation Outlook - Pet Diabetes Care Devices Market

Device Type	Market Share (2025)
Glucose Monitoring Devices	57.9%

End-User Segment	Market Share (2025)
Veterinary Clinics	46.4%

Competitive Outlook

Company Name	Estimated Market Share (%)
Zoetis Inc.	20-24%
Trividia Health, Inc. (PetTest)	15-19%
Merck Animal Health	12-16%
UltiMed, Inc.	8-12%
i-SENS, Inc.	5-9%
Other Companies (combined)	30-40%

The size of the Wearable Diabetes Devices Market was valued at USD 11 Million in 2023 and is projected to reach USD 20 Million by 2032, with an expected CAGR of > 10.00% during the forecast period. Recent developments include: May 2023: The Beta Bionics iLet ACE Pump and the iLet Dosing Decision Software have been granted clearance by the U.S. Food and Drug Administration for individuals aged six and above who have type 1 diabetes. When combined with a compatible FDA-cleared integrated continuous glucose monitor (iCGM), these two devices will create a novel system known as the iLet Bionic Pancreas. This innovative automated insulin dosing (AID) system employs an algorithm to ascertain and direct the administration of insulin., March 2023: The FDA has approved the Eversense E3 Continuous Glucose Monitoring (CGM) System. This innovative system offers real-time monitoring of blood sugar (glucose) levels and tracks their trends over time. Users can conveniently access this information through a mobile app installed on their smartphone, tablet, or other compatible device.. Key drivers for this market are: Rapidly Increasing Incidence and Prevalence of Diabetes, Technological Advancements in the Market. Potential restraints include: Monopolized Supply Chain and High Cost of Devices. Notable trends are: Rising diabetes prevalence globally is driving the market in forecast years.

The global diabetes devices market size is projected to grow from USD 35.74 billion in 2025 to USD 59.69 billion by 2033, exhibiting a CAGR of 6.62%.
Report Scope:

Report Metric	Details
Market Size in 2024	USD 33.52 Billion
Market Size in 2025	USD 35.74 Billion
Market Size in 2033	USD 59.69 Billion
CAGR	6.62% (2025-2033)
Base Year for Estimation	2024
Historical Data	2021-2023
Forecast Period	2025-2033
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered	By Type,By Distribution Channel,By Application,By Region.
Geographies Covered	North America, Europe, APAC, Middle East and Africa, LATAM,
Countries Covered	U.S., Canada, U.K., Germany, France, Spain, Italy, Russia, Nordic, Benelux, China, Korea, Japan, India, Australia, Taiwan, South East Asia, UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria, Brazil, Mexico, Argentina, Chile, Colombia,

The Diabetes Devices Market size was valued at USD 32.70 billion in 2023 and is projected to reach USD 54.07 billion by 2032, exhibiting a CAGR of 7.45 % during the forecasts period. Recent developments include: In May 2023, Medtronic has reached an agreement to purchase EOFlow, a manufacturer of insulin devices. Integrating EOFlow with Medtronic's Meal Detection Technology algorithm and advanced continuous glucose monitor (CGM) is anticipated to enhance the company's capacity to serve a broader range of people with diabetes , In April 2023, Undbio disclosed its intention to invest USD 100 million in constructing a US-based insulin manufacturing plant. The South Korean firm plans to establish a new facility in West Virginia to produce insulin and distribute its products within the country , In July 2023, CharmHealth and Bioverge have jointly invested in My Diabetes Tutor, a startup dedicated to improving the lives of individuals with diabetes .

The size of the Spain Diabetes Devices Market market was valued at USD 0.71 Million in 2024 and is projected to reach USD 1.17 Million by 2033, with an expected CAGR of 7.41% during the forecast period. Recent developments include: February 2024: DexCom introduced its real-time continuous glucose monitoring (CGM) system Dexcom ONE+ in Spain, Belgium, and Poland. Additionally, the company announced that the device is scheduled to be released in the Netherlands during the week commencing 12 February. Dexcom stated that Dexcom ONE+ will be launched in the Middle East, Africa, and various other European nations in the upcoming months., November 2022: The Eversense E3 continuous glucose monitor (CGM) was approved by the FDA and it received a CE Mark approval in Europe for people with diabetes aged 18 and older., June 2022: Senseonics received a CE mark for a 6-month CGM implant. Ascensia Diabetes Care, which signed up to sell Eversense in 2020, was expected to distribute the diabetes device in countries including Germany, Italy, and Spain, where it was laying the groundwork for launch through sales conferences and changes to its distribution model.. Key drivers for this market are: Increasing Number of Preterm and Low-weight Births, Advanced Technology in Fetal and Prenatal Monitoring. Potential restraints include: Stringent Regulatory Procedures. Notable trends are: Monitoring Devices Hold Highest Market Share in Spain Diabetes Care Devices Market in the current year.

Find detailed analysis in Market Research Intellect's Diabetes Care Devices Market Report, estimated at USD 45.3 billion in 2024 and forecasted to climb to USD 75.5 billion by 2033, reflecting a CAGR of 6.8%.Stay informed about adoption trends, evolving technologies, and key market participants.

U.S. Diabetes Devices market is expected to surge $44.36 Billion by 2032, exhibiting a CAGR of 6.5% during the forecast period.

The India diabetes devices market, valued at $2.20 billion in 2025, is projected to experience robust growth, driven by rising diabetes prevalence, increasing awareness of advanced diabetes management technologies, and improving healthcare infrastructure. The market's Compound Annual Growth Rate (CAGR) of 2.28% from 2025 to 2033 reflects a steady expansion, influenced by factors such as government initiatives promoting diabetes awareness and management, and the increasing affordability of innovative devices like continuous glucose monitoring (CGM) systems. This growth is further propelled by the expanding adoption of insulin pumps and improved self-monitoring blood glucose (SMBG) devices offering greater accuracy and convenience. While challenges remain, such as affordability constraints for certain segments of the population and the need for enhanced patient education programs, the overall market trajectory points towards significant expansion over the forecast period. The market segmentation highlights the significant roles of monitoring devices (glucometers, test strips, lancets, and CGM systems) and management devices (insulin pumps, syringes, cartridges, and pens). Major players such as Becton Dickinson, Medtronic, Insulet, and Abbott are actively engaged in technological advancements and market expansion strategies, contributing to the dynamic and competitive landscape of the Indian diabetes devices market. The increasing penetration of digital health technologies also contributes positively to market growth, as does increased awareness of the benefits of early diagnosis and management. The substantial market size and growth trajectory indicate a lucrative opportunity for both established players and new entrants. However, success will require a strong focus on addressing affordability concerns, improving healthcare access, and developing targeted marketing and educational programs to reach diverse populations across India's varied socio-economic landscape. Companies that successfully navigate these aspects and leverage technological advancements will be best positioned to capture significant market share. The sustained growth reflects not only the increasing prevalence of diabetes but also a rising demand for improved disease management solutions and an evolving healthcare ecosystem in India. Recent developments include: November 2023: Terumo India, the Indian subsidiary of Terumo Corporation, a renowned player in the field of medical technology, unveiled today the introduction of the Insulin Syringe, a sterile delivery tool designed for patients in need of frequent insulin injections. This move sets a new standard in enhancing patient comfort and adherence to therapy., March 2022: Medtronic India launched the MiniMed 780G, a next-generation closed-loop insulin pump system. The MiniMed 780G system is a next-generation closed-loop insulin pump system for the treatment of type-1 diabetes in people aged 7-80 years.. Notable trends are: Increasing use of monitoring devices in India.

The Diabetes Devices Market size is expected to reach a valuation of USD 63.0 billion in 2033 growing at a CAGR of 8.00% . The Diabetes Devices Market research report classifies market by share, trend, demand, forecast and based on segmentation.

The size of the Diabetes Devices Market was valued at USD 32 billion in 2023 and is projected to reach USD 54.14 billion by 2032, with an expected CAGR of 7.8% during the forecast period. Recent developments include: April 2023:Abbott, Camdiab, and Ypsomed announced a partnership in order to develop and market an integrated automated insulin delivery (AID) system in European countries. The system will combine Abbott’s Freestyle Libre three continuous glucose monitoring (CGM) system with CamDiab’s CamAPS FX algorithm and Ypsomed’s YpsoPump insulin pump., March 2023:Dexcom and Tandem Diabetes Care announced a partnership to develop and commercialize a closed-loop insulin delivery system. The system will combine Dexcom's G7 CGM system with Tandem's t:slim X2 insulin pump and control-IQ advanced hybrid closed-loop technology., February 2023:Insulet and Medtronic announced a partnership to develop and commercialize a closed-loop insulin delivery system. The system will combine Insulet’s Omnipod five-tubeless insulin pump with Medtronic's Guardian Connect CGM system and its Adaptive Insulin Delivery Technology.. Notable trends are: Growing prevalence of diabetes globally is driving the market growth.

The Italy Diabetes Devices Market Report Segments the Industry Into Device Type (Management Devices and Monitoring Devices), End User (Hospital & Clinics, Home-Care Settings, and More), Diabetes Type (Type 1 Diabetes, Type 2 Diabetes, and Gestational & Other Specific Types). The Market Sizes and Forecasts are Provided in Terms of Value (USD).